Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
11 2월 2022 - 9:40PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of February 2022
Commission File Number: 001-36622
PROQR THERAPEUTICS N.V.
Zernikedreef 9
2333 CK Leiden
The Netherlands
Tel: +31 88 166 7000
(Address, Including Zip Code, and Telephone
Number,
Including Area Code, of Registrant’s Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F x
Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): o
On February 11, 2022, ProQR Therapeutics N.V. (the
“Company”) issued a press release titled, “ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of
Sepofarsen in CEP290-mediated LCA10.” A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein
by reference.
The Company hereby incorporates by reference the
information contained herein into the Company’s registration statements on Form F-3 (File No. 333-260775, File No. 333-260780
and File No. 333-248740).
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
PROQR THERAPEUTICS N.V.
|
|
|
|
|
|
Date: February 11, 2022
|
By:
|
/s/ Smital Shah
|
|
|
|
Smital Shah
|
|
|
|
Chief Financial Officer
|
INDEX TO EXHIBITS
ProQR Therapeutics NV (NASDAQ:PRQR)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
ProQR Therapeutics NV (NASDAQ:PRQR)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025
